The third and final segment of a longer conversation between Susannah Streeter and Philippe Wolgen, CEO of the CLINUVEL Group, focuses on governance, risk management, building a “just culture” around core values and his vision for the Company.
In case you missed it, Part 1 focuses on the Company’s approach to navigating shifting markets and unexpected events, and the commercialisation of CLINUVEL’s lead product, including interactions with England’s National Institute for Health and Care Excellence (NICE) and a landmark decision in 2017. Watch Part 1 here.
Part 2 focuses on the investment required to develop novel drugs, how CLINUVEL is differentiating itself from other biotech companies, and the effects of capital markets on the valuation of a life science company such as CLINUVEL. Watch Part 2 here.